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Abstract Our understanding of the antigen presentation pathway has recently been enhanced
with the identification that the tapasin-related protein TAPBPR is a second major histocompatibility
complex (MHC) class I-specific chaperone. We sought to determine whether, like tapasin, TAPBPR
can also influence MHC class I peptide selection by functioning as a peptide exchange catalyst. We
show that TAPBPR can catalyse the dissociation of peptides from peptide-MHC I complexes,
enhance the loading of peptide-receptive MHC I molecules, and discriminate between peptides
based on affinity in vitro. In cells, the depletion of TAPBPR increased the diversity of peptides
presented on MHC I molecules, suggesting that TAPBPR is involved in restricting peptide
presentation. Our results suggest TAPBPR binds to MHC I in a peptide-receptive state and, like
tapasin, works to enhance peptide optimisation. It is now clear there are two MHC class I specific
peptide editors, tapasin and TAPBPR, intimately involved in controlling peptide presentation to the
immune system.
DOI: 10.7554/eLife.09617.001
Introduction
Major histocompatibility complex (MHC) class I molecules convey a selection of the peptidome of a
cell to the immune system. As well as being of crucial importance for the detection of intracellular
pathogens, particularly viruses, it is now apparent that peptide presentation by MHC class I is
extremely relevant in the recognition of tumours (Ro¨tzschke et al., 1990; Duan et al., 2014;
Gubin et al., 2014; Snyder et al., 2014; Yadav et al., 2014). Despite this, the molecular mecha-
nisms controlling peptide selection for immune recognition are still poorly understood. Currently,
the loading of peptide onto MHC class I is known to be orchestrated by the co-factor tapasin and is
thought to occur predominantly within the peptide loading complex (PLC) in the endoplasmic reticu-
lum (Sadasivan et al., 1996; Li et al., 1997; Ortmann et al., 1997; Lehner et al., 1998; Tan et al.,
2002). Tapasin enhances the rate and the extent of MHC class I peptide loading and improves the
discrimination that occurs between peptides to ensure MHC class I molecules are loaded with high-
affinity peptides, thus prolonging cell surface expression of MHC class I molecules (Williams et al.,
2002; Howarth et al., 2004; Chen and Bouvier, 2007; Wearsch and Cresswell, 2007;
van Hateren et al., 2013). MHC class I allomorphs differ in their dependence on tapasin for efficient
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peptide loading (Greenwood et al., 1994; Peh et al., 1998; Williams et al., 2002). Furthermore,
the ability to select and assemble with an optimal peptide cargo in the absence of tapasin is
inversely correlated to the enhancement observed in the presence of tapasin (Williams et al., 2002;
van Hateren et al., 2013; Rizvi et al., 2014).
It has recently become apparent that, in addition to tapasin, there is a second MHC class I-spe-
cific chaperone, the tapasin-related protein TAPBPR (Boyle et al., 2013). In contrast to tapasin,
TAPBPR is not an integral component of the peptide loading complex and cannot compensate for
the loss of tapasin (Boyle et al., 2013; Hermann et al., 2013). Currently, the precise function of
TAPBPR in the MHC class I pathway is unknown (Hermann et al., 2015). A functional role in MHC
class I antigen presentation is supported by the finding that the presence of TAPBPR slows the
anterograde trafficking of MHC class I and prolongs the association of MHC class I with the PLC.
This raises the possibility that TAPBPR serves as an additional quality control checkpoint in the MHC
class I antigen presentation pathway (Boyle et al., 2013). Although tapasin and TAPBPR only share
22% identity (Teng et al., 2002), both bind MHC class I, and their orientation on MHC class I is simi-
lar (Dong et al., 2009; Hermann et al., 2013). This shared orientation raises the possibility that
there is some common functionality between the two molecules, particularly in regard to the ability
to influence the peptide repertoire presented on MHC class I. Here, we sought to determine
whether, like tapasin, TAPBPR has a peptide editing function.
Results
Expression and purification of TAPBPR
In order to test whether TAPBPR has peptide editing functionality we chose an approach analogous
to that previously established for tapasin, namely a cell free in vitro assay that allows monitoring of
peptide binding to MHC class I in real time via fluorescence anisotropy (Chen and Bouvier, 2007).
Due to the intrinsically low affinity between tapasin and MHC class I molecules in vitro, soluble tapa-
sin function on MHC class I is only measurable when the two molecules are brought into close prox-
imity via a Jun/Fos leucine zipper (Chen and Bouvier, 2007) or when tapasin is conjugated to ERp57
(Wearsch and Cresswell, 2007). Since TAPBPR is not integrated into the PLC and can be co-immu-
noprecipitated with MHC I (Boyle et al., 2013, Hermann et al., 2013), it is likely that TAPBPR has a
higher affinity for MHC class I than tapasin. We therefore tested whether TAPBPR functioned in vitro
without the need for an artificial intermolecular tether.
To this end, the luminal domains of TAPBPR were cloned into the pHLsec expression vector and
transiently transfected into HEK293F cells. This resulted in the efficient production of a secreted
eLife digest Our immune system protects us from infections and destroys cells that are turning
cancerous. A group of proteins called MHC class I molecules are essential for this protection. These
molecules let the immune system know what is going on inside our cells by displaying chopped up
fragments of proteins (or peptides) on the surface of the cell. If these peptides are from infectious or
disease-causing agents the immune system is triggered into action and can recognise and kill the
cell.
There is still much to discover regarding how MHC molecules choose which peptides to display.
A very complex pathway within our cells controls this displaying of peptides to the immune system.
Recently, a protein called TAPBPR was identified as a new player in MHC class I biology, but its role
was unclear.
Hermann, van Hateren et al. now reveal that TAPBPR plays a central role in restricting which
peptides are loaded onto and presented by MHC class I molecules. The results suggest that
TAPBPR acts as a quality control checkpoint, closely monitoring and ensuring that the loaded
peptide is stable within the MHC class I molecule. The discovery of TAPBPR’s role in peptide
selection increases our understanding of how peptides are chosen and stabilized, and sets the stage
for learning more about how cells decide which peptides to reveal to the immune system.
DOI: 10.7554/eLife.09617.002
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form of TAPBPR with a C-terminal His-tag, allowing for purification from the culture supernatant
using Ni-affinity and size exclusion chromatography. TAPBPR protein eluted as a single major peak
of high purity as verified by Coomassie staining following sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) (Figure 1A). TAPBPRTN5 in which the isoleucine at position 261 was
mutated to lysine, which inhibits the interaction of TAPBPR with MHC class I (Hermann et al., 2013),
was produced in the same manner and was also efficiently expressed and produced a major single
protein peak following size-exclusion chromatography (Figure 1B). Differential scanning fluorimetry
revealed melting temperatures for TAPBPR and TAPBPRTN5 to be between 51.5˚C and 52.5˚C indi-
cating that the single point mutation did not adversely affect TAPBPR folding (Figure 1C). These
mammalian-expressed, purified TAPBPR proteins were used in subsequent fluorescence anisotropy
experiments to characterise the equilibrium and kinetic parameters between MHC class I and differ-
ent peptide ligands.
TAPBPR enhances peptide dissociation from HLA-A2 in vitro
To investigate if TAPBPR is able to directly edit peptides on MHC class I molecules in a manner simi-
lar to that attributed to tapasin, we adapted the in vitro peptide exchange assay previously devel-
oped for measuring tapasin function (Chen and Bouvier, 2007). Using fluorescent polarisation we
tested whether TAPBPR enhanced peptide dissociation from HLA-A2, an allomorph that co-immuno-
precipitates readily with TAPBPR (Hermann et al., 2013). HLA-A*02:01 molecules were loaded with
the fluorescent peptide FLPSDC*FPSV (C* indicates the position of the fluorophore) before excess
unlabelled FLPSDCFPSV peptide was added in the presence or absence of TAPBPR. Dissociation of
FLPSDC*FPSV was only apparent in the first six hours in the presence of competitor peptide and
TAPBPR (Figure 2A). Dissociation of FLPSDC*FPSV was also observed when a vast excess of unla-
belled NLVPMVATV was used in the presence of TAPBPR (Figure 2B). To ensure the enhancement
of peptide dissociation was a consequence of direct interaction between TAPBPR and HLA-A2, we
repeated the peptide dissociation assays using TAPBPRTN5 (I261K) which inhibits the ability of
TAPBPR to bind to HLA-A2 (Hermann et al., 2013). No enhancement in the dissociation of
FLPSDC*FPSV was observed in the presence of TAPBPRTN5 (red line Figure 2B). Thus the ability of
TAPBPR to enhance peptide dissociation is a direct consequence of TAPBPR binding to HLA-A2.
TAPBPR enhances peptide association with HLA-A2 in vitro
Next we examined the effect that TAPBPR has on the kinetics of peptide association with HLA-A2.
To test this, HLA-A*02:01 molecules refolded with a UV conditional ligand were made peptide-
receptive by photolysis and the binding of the fluorescent peptide FLPSDC*FPSV was monitored by
fluorescence polarisation in the absence or presence of TAPBPR. We found that TAPBPR catalysed
binding of FLPSDC*FPSV to peptide-receptive HLA-A*02:01 (Figure 2C). In contrast, no enhance-
ment in the association of FLPSDC*FPSV with HLA-A2 was observed in the presence of TAPBPRTN5
Figure 1. Expression of TAPBPR. Size exclusion chromatograms of (A) TAPBPR and (B) TAPBPRTN5 purified from cell culture supernatants. The protein
peaks were analysed by SDS-PAGE followed by Coomassie staining. (C) Differential scanning fluorimetry of TAPBPR and TAPBPRTN5 demonstrate
equivalent thermal denaturation profiles. The data is representative of two independent experiments.
DOI: 10.7554/eLife.09617.003
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(Figure 2C), further demonstrating that a direct association between TAPBPR and HLA-A2 is
required for TAPBPR to influence HLA-A2 peptide binding characteristics.
TAPBPR enhances the selection of high affinity peptide by HLA-A2 in
vitro
To ascertain whether TAPBPR is able to discriminate between peptides, competition assays were
performed in which peptide-receptive HLA-A*02:01 molecules were incubated with a mix of two
peptides; 0.125 mM of the high affinity labelled peptide FLPSDC*FPSV, and a variable concentration
of the peptide NLVPMVATV, which binds HLA-A*02:01 with lower affinity than FLPSDCFPSV. In the
presence of TAPBPR, NLVPMVATV became a poorer competitor (Figure 2D). TAPBPRTN5 had no
Figure 2. TAPBPR functions as a peptide loading catalyst and peptide editor for HLA-A2. (A,B) Dissociation, (C) association and (D) peptide
competition of fluorescent peptide FLPSDC*FPSV on HLA-A*02:01 in the absence or presence of TAPBPR or TAPBPRTN5 as measured by fluorescence
polarisation. (A) 0.15 mM HLA-A*02:01fos molecules were mixed with 1.2 mM human b2m and loaded with 0.1 mM FLPSDC*FPSV and (B) 0.5 mM HLA-
A*02:01 molecules were loaded with 0.125 mM FLPSDC*FPSV. The complexes were then split and incubated with 1000 fold molar excess of (A)
FLPSDCFPSV or (B) NLVPMVATV with either A) buffer (No protein) or supplemented with 0.75 mM TAPBPR, or (B) buffer (No protein) or supplemented
with 0.25 mM TAPBPR or TAPBPRTN5. Note, the slight difference in dissociation rate observed in A & B is likely to be related to the concentration of
TAPBPR used in each experiment and not to the sequence of the competing peptide used. The data shown in Figure 2A,B is representative of 13
independent experiments, which all produced similar results. (C) 0.5 mM HLA-A*02:01 molecules were made peptide receptive and then the binding of
0.125 mM FLPSDC*FPSV was followed in the presence or absence of 0.05 mM TAPBPR or TAPBPRTN5. One representative association experiment of 13
experiments is shown. (D) 0.5 mM HLA-A*02:01 molecules were made peptide-receptive and incubated with 0.125 mM high affinity peptide
FLPSDC*FPSV and various concentrations of the lower affinity competing peptide NLVPMVATV (0–20 mM) in presence or absence of 0.25 mM TAPBPR
or TAPBPRTN5. One of two experiments is shown. (E–G) Comparison of the dissociation of seven peptides from HLA-A*02:01fos in the presence or
absence of TAPBPR or tapasin-Jun as performed in Figure 2—figure supplement 1. The results of three (E) and four (F,G) independent experiments
were combined and are shown. Data from each experiment was processed in GraphPad Prism using one-phase exponential decay non-linear
regression. The half-lives that were calculated for the dissociation of the indicated peptide in the presence of either (E) Competitor only, (F) Competitor
and Tapasin-Jun or (G) Competitor and TAPBPR were plotted as a percentage of the half-life calculated for the dissociation of KLWEAESK*L in the
equivalent condition. Error bars show the standard deviation of the relative half-lives measured in the different experiments. While there were slight
modifications of experimental conditions between replicate experiments, results consistent with the presented results were observed.
DOI: 10.7554/eLife.09617.004
The following figure supplement is available for figure 2:
Figure supplement 1. Dissociation of seven different peptides from HLA-A*02:01fos in the presence or absence of TAPBPR or Tapasin-Jun.
DOI: 10.7554/eLife.09617.005
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effect on peptide competition (Figure 2D). These results suggest that, like tapasin (Chen and Bouv-
ier, 2007), TAPBPR can enhance the selection of high affinity peptides for binding to MHC I in vitro.
Comparison of TAPBPR and tapasin-jun mediated peptide dissociation
from HLA-A2 in vitro
Next we compared the ability of TAPBPR or tapasin-jun to enhance dissociation of FLPSDC*FPSV
and a panel of six additional peptides bound to HLA-A2. The dissociation rates of all peptides were
enhanced in the presence of TAPBPR and in the presence of tapasin-jun as compared to competing
peptide alone (Figure 2—figure supplement 1). However, peptide specific differences were appar-
ent in the ability of tapasin-jun and TAPBPR to enhance dissociation. As different concentrations of
active tapasin-jun and TAPBPR proteins were present in these assays, it was not possible to directly
compare the dissociation half-lives of specific peptides in the presence of tapasin-jun with TAPBPR.
Therefore we compared the hierarchies of dissociation relative to one peptide (KLWEAESK*L) over
four independent experiments. This revealed reproducible differences in the hierarchies of peptide
dissociation between tapasin-jun and TAPBPR on HLA-A2 (Figure 2E–G). Interestingly the half-life
hierarchy for tapasin was similar to the hierarchy observed in the absence of either cofactor (compet-
itor only) (Figure 2E,F), with the exception of the dissociation of GLDDIKDLK*V whose dissociation
was relatively much slower in the presence of tapasin-jun compared to the other peptides than was
observed in the presence of competitor only. This suggests that tapasin enhancement of peptide
dissociation generally parallels peptide-MHC complex stability, as previously reported
(Howarth et al., 2004). However, the half-life of peptides in the presence of TAPBPR does not fol-
low this trend (Figure 2G). Specifically we observed that in comparison to the other peptides,
TAPBPR enhanced dissociation of KLVK*EVIAV to a much smaller extent than was apparent in the
presence of tapasin-jun or absence of either cofactor (competitor only) (Figure 2E–G). The same was
also true of FLPSDC*FPSV (Figure 2E–G). Taken together our results suggest firstly that both tapasin
and TAPBPR enhance peptide dissociation, and secondly that there are subtle differences in regard
to their peptide specificity.
TAPBPR interacts with HLA-B as well as HLA-A molecules
We previously reported that TAPBPR has preference for HLA-A68 over HLA-B15 expressed in HeLa
cells (Boyle et al., 2013). We wondered if TAPBPR generally exhibited preference for HLA-A allo-
morphs or whether TAPBPR might interact with HLA-B allomorphs. To explore this, we expressed a
small panel of individual HLA allomorphs in the MHC class I negative cell line 721.221, and deter-
mined their interaction with endogenous TAPBPR, in a system in which competition between MHC
class I allomorphs is absent. Immunoprecipitation of TAPBPR, followed by western blotting for MHC
class I, confirmed the strong association between TAPBPR and the HLA-A allomorphs HLA-A2 and
HLA-A68 (Figure 3). However, an association
between TAPBPR and HLA-B allomorphs was
also detected, although this was weaker (HLA-B8
and -B15), or below the limits of detection (HLA-
B40), compared to that for HLA-A2 (Figure 3).
Therefore, although there is clearly a strong asso-
ciation with those HLA-A allomorphs tested,
TAPBPR interacts with a broader range of HLA
molecules than originally appreciated
(Boyle et al., 2013).
TAPBPR function on HLA-B8 in
vitro
Given the interactions detected between TAPBPR
and the studied HLA-B allomorphs, we asked
whether TAPBPR was involved in peptide selec-
tion on HLA-B*08:01, an allomorph which inter-
acts weakly with TAPBPR (Figure 3) and which is
well-characterised in regard to tapasin function
Figure 3. TAPBPR associates with HLA-A and HLA-B
molecules. TAPBPR was isolated by
immunoprecipitation (using R014) from the MHC class I
negative cell line 721.221 and 721.221 stably
transduced with HLA-A2, A68, B8, B15 or B40. Western
blot analysis was performed for TAPBPR and the MHC
class I heavy chain (using HCA2 and HC10) on lysates
(labelled lys) and TAPBPR immunoprecipitates as
indicated. The data is representative of three
independent experiments.
DOI: 10.7554/eLife.09617.006
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(Greenwood et al., 1994; Lehner et al., 1998; Peh et al., 1998; Chen and Bouvier, 2007;
Wearsch and Cresswell, 2007). We first asked whether TAPBPR enhanced peptide dissociation
from HLA-B*08:01fos molecules. We found that dissociation of EIYK*RWIIL was enhanced in the
presence of TAPBPR (Figure 4A and Figure 4—figure supplement 1A). No enhancement of the dis-
sociation of EIYK*RWIIL was observed in the presence of TAPBPR using HLA-B8:01-T134K in which
the T134 residue had been mutated to lysine, which abrogates binding of TAPBPR to MHC I
(Hermann et al., 2013) (Figure 4B and Figure 4—figure supplement 1B), demonstrating that the
enhanced peptide dissociation was dependent on a direct interaction between TAPBPR and HLA-
B8. We also tested the ability of TAPBPR to enhance dissociation of two additional peptides,
ELRSRK*WAI and FLRGRK*YGL from HLA-B*08:01. The dissociation of ELRSRK*WAI was not altered
in the presence of TAPBPR (Figure 4C and Figure 4—figure supplement 1C) and only a very slight
change in dissociation of FLRGRK*YGL was observed in the presence of TAPBPR (Figure 4D and
Figure 4—figure supplement 1D). Therefore, our results suggest that TAPBPR can enhance peptide
dissociation from HLA-B8 but that this effect is peptide specific. Tapasin has also been reported to
exhibit peptide specificity in regard to peptide dissociation (Chen and Bouvier, 2007). Like TAPBPR,
tapasin-jun accelerated dissociation of fluorescein isothiocyanate (FITC) labelled versions of both
EIYK*RWIIL and FLRGRK*YGL from HLA-B*08:01fos, while the dissociation of ELRSRK*WAI was
insensitive to tapasin-jun (Chen and Bouvier, 2007).
Figure 4. TAPBPR can function as a peptide loading catalyst and peptide editor for HLA-B8. (A–D) Dissociation, (E–G) association and (H) peptide
competition of fluorescent peptides on HLA-B*08:01 in the absence or presence of TAPBPR. 2 mM HLA-B*08:01fos or HLA-B*08:01fos T134K molecules
were mixed with 20 mM human b2m and made peptide receptive then loaded with 1 mM (A,B) EIYK*RWIIL (C) ELRSRK*WAI or (D) FLRGRK*YGL.
Dissociation was subsequently followed after the addition of a 250 molar excess of (A,B) EIYKRWIIL (C) ELRSRKWAI, or (D) FLRGRKYGL in the absence
or presence of 0.75 mM TAPBPR. A total of eight dissociation experiments have been conducted for wild-type HLA B*08:01fos, and the T134K mutant
was included in six of these experiments. (E–G) 0.6 mM HLA B*08:01fos molecules were mixed with 6 mM human b2m and made peptide-receptive, then
the binding of 1 mM of (E) EIYK*RWIIL, (F) ELRSRK*WAI or (G) FLRGRK*YGL was followed in the absence or presence of 0.175 mM TAPBPR. One of
three experiments is shown. (H) 0.6 mM HLA-B*08:01fos molecules were mixed with 0.6 mM human b2m and were made peptide-receptive, then
incubated with 0.1 mM high affinity peptide ELRSRK*WAI and various concentrations of the lower affinity competing peptide EIYKRWIIL (0–25 mM) in
presence or absence of 0.3 mM TAPBPR. One of six experiments is shown. Fluorescence polarisations measurements were taken after being left at room
temperature overnight. While there were slight modifications of experimental conditions between replicate experiments, results consistent with the
presented results were observed.
DOI: 10.7554/eLife.09617.007
The following figure supplement is available for figure 4:
Figure supplement 1. Dissociation of three different peptides from HLA B*08:01fos in the presence or absence of TAPBPR.
DOI: 10.7554/eLife.09617.008
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As with HLA-A2, we observed that TAPBPR could enhance peptide binding to peptide-receptive
HLA-B*08:01fos molecules. However, this was only observed with EIYK*RWIIL (Figure 4E) and the
binding of ELRSRK*WAI or FLRGRK*YGL to peptide receptive HLA-B*08:01fos was not altered in
the presence of TAPBPR (Figure 4F,G). This contrasts with the results previously published by Chen
and Bouvier, who observed that tapasin-jun enhanced binding of FITC labelled versions of ELRSRK*-
WAI and FLRGRK*YGL to peptide-receptive HLA-B*08:01fos molecules (Chen and Bouvier, 2007).
Taken together the data indicate that TAPBPR can enhance the loading of peptide onto HLA-
B*08:01, and that this is peptide specific. Furthermore, there are differences in peptide specificity
between tapasin and TAPBPR with respect to HLA-B*08:01 peptide-loading.
Finally we showed that, like tapasin (Chen and Bouvier, 2007), TAPBPR increased peptide
exchange on HLA-B*08:01 since the low affinity peptide EIYKRWIIL became a poorer competitor
against the high affinity labelled peptide ELRSRK*WAI in the presence of TAPBPR (Figure 4H).
TAPBPR expression alters the peptide repertoire presented by MHC
class I on cells
Given that TAPBPR functions as a peptide exchange catalyst for MHC class I in vitro, we next deter-
mined if TAPBPR expression had any effect on the peptide repertoire expressed by MHC class I mol-
ecules in cells. To do this, we created a HeLa cell line in which TAPBPR was knocked out using the
clustered regularly interspaced short palindromic repeats (CRISPR) system. We found that upon
treatment with IFN-g, TAPBPR expression was induced in HeLa, but not in the HeLa-TAPBPR KO line
(Figure 5A). Tapasin expression was not affected by the sgRNA targeted to TAPBPR (Figure 5A). In
the absence of TAPBPR, cell surface expression of MHC class I in IFN-g treated HeLa did not signifi-
cantly change as determined by W6/32 staining and flow cytometry (Figure 5B). When the amino
acid sequences of the peptides eluted from MHC class I molecules from IFN-g treated HeLa and
HeLa-TAPBPR KO cells were compared, the most noticeable difference was a change in the diversity
of peptides isolated (Figure 5C). In IFN-g treated HeLa cells, we isolated 1607 different peptides on
MHC class I, compared with 2074 in IFN-g treated HeLa-TAPBPR KO cells (Figure 5C). 1398 pepti-
des were shared between the two cell lines, but 209 peptides were unique to HeLa and 676 were
unique to HeLa-TAPBPR KO (Figure 5C). When the peptides were subdivided into those predicted
to bind to HLA-A*68:02 or HLA-B*15:03 based on anchor sequences, an increased repertoire was
observed for both allomorphs in the absence of TAPBPR (Figure 5C). Consistent with these findings,
a similar pattern of increased peptide diversity was also observed in IFN-g treated HeLa-S cells upon
TAPBPR depletion using shRNA to TAPBPR (Figure 5—figure supplement 1).
To complement these findings we compared the amino acid sequences of peptides eluted from
MHC class I molecules isolated from HeLa and HeLa cells over-expressing TAPBPR by mass spectrom-
etry. Again the most obvious difference was a change in the diversity of peptides isolated (Figure 5D).
We found the total number of different peptides isolated from MHC class I was decreased in cells
over-expressing TAPBPR, from 819 MHC class I restricted peptides from HeLa cells down to 296 MHC
class I restricted peptides isolated from HeLa cells over-expressing TAPBPR. 210 peptides were shared
between the two cell lines (Figure 5D). Again, when these peptides were further sub-divided into
those predicted to bind to HLA-A*68:02 and -B*15:03 based on their motif, an increased repertoire
was observed for both allomorphs in the absence of TAPBPR (Figure 5D). Taken together, these
results suggest that TAPBPR restricts the peptide repertoire presented on MHC class I molecules. We
compared the anchor residues found at the P2 and C-terminal (PW) position of the shared peptides,
eluted from either TAPBPR negative or TAPBPR expressing cells, which will presumably be permitted
release in TAPBPR expressing cells, with unique peptides exclusively eluted from TAPBPR negative
cells (HeLa or HeLa-TAPBPR KO+IFN-g), which are therefore usually removed or restricted by TAPBPR.
We found there was an enhancement of canonical anchor residues in the peptides eluted from
TAPBPR expressing cells (Figure 5E–H). For example, in IFN-g treated HeLa cells 53% of the shared
peptides predicted to be bound to HLA-A*A68:02 (which had presumably been subjected to TAPBPR
function) had classic anchor residues (P2 = threonine or valine, PW = valine or leucine) compared to
43% of the peptides found exclusively in TAPBPR deficient cells which are the peptides that TAPBPR
usually restricts (Figure 5E). More striking was the restriction of peptides predicted to be bound by
HLA-B*15:03 in cells over-expressing TAPBPR (Figure 5H) with only 5% of the peptides eluted exclu-
sively from TAPBPR deficient cells (i.e. the TAPBPR restricted peptides) containing classical anchor
motifs (P2 = glutamine or lysine, PW = tyrosine or phenylalanine) compared to 24% of the peptides
Hermann et al. eLife 2015;4:e09617. DOI: 10.7554/eLife.09617 7 of 22
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eluted from TAPBPR over expressing cells (i.e. the TAPBPR permitted peptides). This suggests
TAPBPR restriction in vivo helps to remove some peptides of lower affinity and therefore assists in
Figure 5. TAPBPR expression alters the peptide repertoire presented by MHC class I on cells. (A) The TAPBPR:MHC class I complex was
immunoprecipitated from IFN-g treated HeLa and HeLa-TAPBPR KO cells. Western blot analysis was performed for TAPBPR (mouse anti-TAPBPR),
tapasin (Rgp48N), MHC class I (HC10) and calnexin on lysates and TAPBPR immunoprecipitates as indicated. The data is representative of three
independent experiments. (B) Cytofluorometric analysis of MHC class I detected with W6/32 on IFN-g treated HeLa (Blue line) and HeLa-TAPBPR KO
cells (Red line). Staining with an isotype control on both cell lines (dashed lines) is included as a control. (C,D) Peptide-MHC class I complexes were
isolated by affinity chromatography using W6/32 from (C) IFN-g treated HeLa and HeLa-TAPBPR KO cells or (D) HeLa and HeLa overexpressing WT-
TAPBPR. Eluted peptides were analysed using LC-MS/MS. Graphs show the total number of peptides and also the number of peptides assigned as
HLA-A*68:02 and HLA-B*15:03 binders based on their peptide motifs using the online programme NetMHC. The number of peptides shared between
the cell lines (white bar) and the number of peptides unique to each cell line (coloured bars) is shown. The data was generated from tandem MS
analysis performed five times on one immunoprecipitate. Two independent biological repeats have been performed in two different cell lines (HeLa-S
cells shown in Figure 5—figure supplement 1, and KBM-7 cells shown in Figure 6) in which a similar pattern of increased peptide diversity in TAPBPR
depleted cells was observed. (E–H) Conservation of P2 and C-terminal anchor residues (PW). Plots show prevalence of classic peptide anchors on (E,F)
HLA-A*68:02 or (G, H) HLA-B*15:03. Bars show classic anchor conservation at P2, PW and P2/PW combined for (E,G) shared peptides found in both IFN-
g treated HeLa and HeLa TAPBPR KO cells (white bar) (presumably permitted expression in the presence of TAPBPR) and peptides unique to HeLa
TAPBPR KO + IFNg cells (red bar) (presumably restricted in the presence of TAPBPR), (F,H) shared peptides found in both HeLa and HeLa over-
expressing TAPBPR (white bar) (presumably permitted expression in the presence of TAPBPR) and peptides unique to HeLa (green bar) (presumably
restricted in the presence of TAPBPR).
DOI: 10.7554/eLife.09617.009
The following figure supplements are available for figure 5:
Figure supplement 1. Increased peptide diversity on MHC class I in the absence of TAPBPR in IFN-g treated HeLa-S cells.
DOI: 10.7554/eLife.09617.010
Figure supplement 2. TAPBPR expression does not influence peptide length.
DOI: 10.7554/eLife.09617.011
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improving peptide selection on MHC class I. We found TAPBPR expression did not have a dramatic
effect on peptide length (Figure 5—figure supplement 2).
Within a cellular environment tapasin and TAPBPR have distinct effects
on peptide selection
We also compared the effect of TAPBPR depletion with tapasin deficiency on the MHC class I peptide
repertoire from IFN-g treated KBM-7 cells (see [Hermann et al., 2013] for knockdown efficiency). Sur-
face expression of HLA-A2 was similar in IFN-g treated wild-type (WT), TAPBPR depleted and tapasin
deficient KBM-7 cells (Figure 6A). While TAPBPR depletion resulted in increased peptide diversity on
HLA-A2 (Figure 6B), tapasin deficiency did not significantly change the total number of peptides pre-
sented on HLA-A2 (Figure 6B), although the peptide repertoire was significantly different between
IFN-g treated WT and tapasin deficient KBM-7 cells (Figure 6C). Surface expression of HLA-B40 was
similar in IFN-g treated WT and TAPBPR depleted cells, but was reduced in tapasin deficient KBM-7
cells (Figure 6D). TAPBPR depletion and tapasin deficiency produced different effects on peptides
presented by HLA-B40 and -C03 in IFN-g treated KBM-7 cells, with TAPBPR depletion increasing pep-
tide diversity and tapasin deficiency decreasing the number of peptides presented (Figure 6E,F). A
similar effect of tapasin deficiency decreasing peptide number has recently been reported for the
mouse MHC I molecule H-2Db and Kb (Kanaseki et al., 2013). Therefore, although in vitro TAPBPR
Figure 6. Distinct alterations to the peptide repertoire expressed on MHC class I molecules in IFN-g treated KBM-
7 cells upon TAPBPR depletion or tapasin deficiency. Cytofluorometric analysis of (A) HLA-A2 expression (detected
with BB7.2) and (D) HLA-B expression (detected with 4E) on the cell surface of WT, TAPBPR stably depleted
(shTAPBPR) and tapasin deficient (TPN-) KBM-7 cells treated with and without IFN-g for 48 hr. The data is
representative of three independent experiments. (B,E) Peptide-MHC class I complexes were isolated using affinity
chromatography using (B) BB7.2 (HLA-A2) and (E) B1.23.2 (HLA-B,-C) from IFN-g treated WT, TAPBPR stably
depleted (shTAPBPR) and tapasin deficient (TPN-) KBM-7 cells. Eluted peptide were analysed using LC-MS/MS.
Graphs show the total number of peptides. The data was generated from tandem MS analysis performed five
times on one immunoprecipitate. Two independent biological repeats comparing the peptide repertoire
expressed on MHC class I under conditions of TAPBPR competency and TAPBPR deficiency in two other cell lines
have been performed (HeLa-M cells shown in Figure 5 and HeLa-S cell shown in Figure 5—figure supplement 1)
in which a similar pattern of increased peptide diversity upon TAPBPR depletion was observed. (C,F) Venn
diagrams show the overlap of peptides on (C) HLA-A2 and (F) HLA-B,-C eluted from IFN-g treated WT, TAPBPR
stably depleted (TAPBPR KD) and tapasin deficient (Tapasin KO) KBM-7 cells.
DOI: 10.7554/eLife.09617.012
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and tapasin both function as peptide exchange
catalysts, within the cellular environment the two
molecules shape the peptide repertoire in distinct
ways.
The MHC I bound to TAPBPR is
peptide-receptive
Given our finding that TAPBPR functions as a
peptide exchange catalyst in vitro and restricts
the peptide repertoire presented on MHC class I
on cells, we next asked if the MHC class I mole-
cules bound to TAPBPR in cells were peptide-
receptive and whether they could be released
from TAPBPR by high-affinity peptide. TAPBPR
was isolated in complex with MHC I from IFN-g
induced KBM-7 cells (which are HLA-A2+), then
incubated in the presence or absence of 100 mM
of the HLA-A2 binding peptide NLVPMVATV.
Western blot analysis of the proteins co-immuno-
precipitated with TAPBPR revealed a >90%
reduction in the amount of HLA-A2 bound to
TAPBPR following the addition of the NLVPMVA-
TV peptide (Figure 7). To ensure this was a con-
sequence of direct peptide binding to HLA-A2,
we tested NLVPMVATV peptide variants in which
the anchor residues at position 2 and 9 were
substituted, thus lowering the avidity of the pep-
tide. Less dissociation of HLA-A2 from TAPBPR was observed using NAVPMVATV (D2) and
NLVPMVATM (D9) peptides, in which one anchor residue had been substituted, while the NAVPM-
VATM (D2/9) peptide, in which both anchor residues were substituted was unable to induce any
HLA-A2 dissociation (Figure 7). Next we asked whether peptide loaded HLA-A2 molecules were
released from TAPBPR following peptide addition by performing a second immunoprecipitation
using BB7.2 from the peptide-treated eluates. Peptide loaded HLA-A2 was released from TAPBPR
upon incubation with the NLVPMVATV peptide but not in the absence of the peptide (lanes 2 and 1
respectively Figure 7). Only trace amounts of peptide loaded HLA-A2:b2m molecules were released
from TAPBPR using the D2 and D9 peptides (lane 3 and 4, Figure 7), while no peptide loaded HLA-
A2 was released from TAPBPR using the D2/9 peptide (lane 5 Figure 7). Together these results dem-
onstrate that MHC I molecules bound to TAPBPR are in a peptide-receptive state and that the asso-
ciation between TAPBPR and MHC I is reduced by high affinity peptide resulting in peptide loaded
MHC I being released from TAPBPR.
Tapasin and TAPBPR work together to optimise surface expression of
MHC class I molecules
HLA allomorphs differ in their dependency on tapasin for efficient surface expression. Previous stud-
ies have reported that, although the quantity of naturally processed peptides stably bound by HLA-
A*02:01 is significantly reduced in the absence of tapasin (Barber et al., 2001), surface expression
of HLA-A2 is relatively unaffected in the absence of tapasin (Greenwood et al., 1994; Barber et al.,
2001). In contrast, HLA-B7 expression is reduced in the absence of tapasin (Rizvi et al., 2014). As
TAPBPR is also involved in peptide selection on MHC class I molecules, we sought to examine the
effect of TAPBPR depletion on surface expression of both HLA-A2 and HLA-B7 in the presence and
the absence of tapasin. To investigate this, 721.221 (tapasin positive, MHC class I negative)
(Shimizu et al., 1988) and 721.220 (tapasin negative, HLA-A, -B negative, but HLA-Cw1 positive)
(Greenwood et al., 1994) cells were transduced with HLA-A2 and -B7 and then depleted of TAPBPR
using shRNA. This resulted in a significant, although not complete, reduction of TAPBPR expression
(Figure 8A). Tapasin expression in 721.221 cells was not altered in cells expressing shTAPBPR
Figure 7. The MHC I bound to TAPBPR is peptide
receptive. The TAPBPR:MHC I complex was
immunoprecipitated from IFN-g induced KBM-7 cells.
Equal aliquots were divided, then incubated -/+ 100
mM (20 mg) of the indicated peptide (WT:NLVPMVATV,
D2: NAVPMVATV, D9: NLVPMVATM, D2/9:
NAVPMVATM) for 30 min at 4˚C. Subsequently all
eluates (- or + peptide) were re-immunoprecipitated
with BB7.2. Extensive washing was performed to
remove any released MHC I before denaturation.
Western blot analysis was performed for TAPBPR, and
HLA-A2 (using HCA2) under reducing conditions. Data
shown are representative of three independent
experiments.
DOI: 10.7554/eLife.09617.013
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(Figure 8A). Consistent with our previous findings in tapasin deficient KBM-7 cells (Hermann et al.,
2013), we found an increased interaction between HLA-A2 and TAPBPR in the absence of tapasin in
the 721 cell line series (compare TAPBPR IP lanes 1 and 3, Figure 8A) which was apparent even
though the expression of TAPBPR appeared to be slightly higher in .220 cells compared to .221
cells. This phenomenon does not appear to be restricted to HLA-A2, as we similarly observed an
increased interaction between HLA-B7 and TAPBPR in the absence of tapasin (compare TAPBPR IP
lanes 1 and 3, Figure 8A). The increased association between TAPBPR and MHC class I occurs
despite the fact that the steady state level of both HLA-B7 and HLA-A2 is severely reduced in the
absence of tapasin (compare lysate lanes 1 and 3, Figure 8A). We found that the steady state level
of HLA-A2 at the cell surface was not affected by TAPBPR depletion in tapasin sufficient cells (left
panel Figure 8B). However, the depletion of TAPBPR in tapasin negative cells resulted in a ~75%
Figure 8. TAPBPR depletion reduces MHC class I stability. (A) The MHC class I negative cell line 721.221 and the tapasin and HLA-A and -B negative
cell line 721.220 were transduced with HLA-A2 and –B7. shRNA specific for TAPBPR (shTAPBPR) was used to produce TAPBPR depleted versions of
these cell lines. TAPBPR was isolated by immunoprecipitation from these four cell lines. Western blot analysis was performed for TAPBPR, tapasin, HLA-
B (3B10.7), HLA-A2 (HCA2), and calnexin on lysates and TAPBPR immunoprecipitates as indicated. This data is representative of three independent
repeats. Cytofluorometric analysis of (B) HLA-A2 (detected with BB7.2) or (C) HLA-B7 (detected with anti-Bw6 antibody) on .221 (A2+ , B7+ ) (grey filled
histogram), .221 (A2+ ,B7+) shTAPBPR (red line histogram), .220 (A2+ ,B7+ ) (blue line histogram), .220 (A2+ ,B7+ ) shTAPBPR (green line histogram).
Staining on the non-transduced 721.221 and 721.220 cells with BB7.2 and Bw6 (grey solid line) or with an isotype control (grey dashed line) are included
as controls. The data is representative of three independent experiments. (D) Thermal stability of HLA-A2 expressed in .221 (A2+ ,B7+ ) and .220 (A2+ ,
B7+) -/+ stable depletion of TAPBPR (shTAPBPR). Cells were radiolabelled for 60 min with [35S] cysteine/methionine, lysed, then equal aliquots of
cleared lysates were either kept at 4˚C or heated at 22˚C, 37˚C or 50˚C for 12 min. Peptide loaded HLA-A2 was immunoprecipitated using BB7.2 post-
preclear. After separation by SDS-PAGE, the signal intensity of the radiolabelled HLA-A2 band was determined by phosphorimaging. The results are
representative of four independent experiments. The graph shows the percentage of peptide loaded HLA-A2 recoverable at each temperature as a
percentage of the signal intensity at 4˚C. Error bars show SEM from four independent experiments. Surface expression of (E) HLA-A2 (detected with
BB7.2) and (F) HLA-B7 (detected with BB7.1) on cells treated with 5 mg/ml brefeldin A (BFA), which inhibits egress of newly assembled molecules from
the ER, for 0, 0.5, 3, 6 and 16 hr. The level of remaining HLA-A2 and HLA-B7 at each time point is expressed as percentage of the mean fluorescence at
time 0. Error bars represent SEM of duplicate samples and the data is representative of three independent experiments.
DOI: 10.7554/eLife.09617.014
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decrease in cell surface expression of HLA-A2 (right panel Figure 8B). In contrast, using an antibody
to the Bw6 epitope we observed a significant decrease in the surface expression of HLA-B7 upon
depletion of TAPBPR, even in the presence of tapasin (left panel Figure 8C). This is despite the poor
ability of HLA-B7 to co-immunoprecipitate with TAPBPR, as compared with HLA-A2 with TAPBPR
(Figure 8A). Only residual expression of HLA-B7 was observed upon the depletion of TAPBPR in the
tapasin negative cell 721.220 (right panel Figure 8C). These results suggest that HLA allomorphs dif-
fer in their dependency on TAPBPR, and that tapasin and TAPBPR work together to optimise surface
expression of MHC class I molecules.
TAPBPR depletion reduces MHC class I stability
Comparison of the anchor residues in TAPBPR-permitted versus TAPBPR-restricted peptides sug-
gests TAPBPR enhances the selection of peptides with canonical anchor residues and consequently
may help reduce the cell surface presentation of peptides with lower affinity (Figure 5E–H). To test
directly whether HLA molecules are indeed loaded with low affinity peptides in the absence of
TAPBPR, we compared the stability of MHC class I molecules in the presence and absence of
TAPBPR. First, the thermal stability of HLA-A2 molecules expressed in TAPBPR-competent and
TAPBPR-depleted cells in the presence or absence of tapasin was investigated by heating lysates of
radiolabelled cells for a short time, followed by immunoprecipitation with BB7.2 (specific for peptide
loaded HLA-A2). We found that the thermal stability of HLA-A2 was reduced in TAPBPR depleted
cells (compare grey bar with the red bar in Figure 8D). As the thermal stability of MHC class I corre-
lates with the affinity of its peptide cargo (Williams et al., 2002), these results support the hypothe-
sis that TAPBPR assists in the selection of stable peptides on MHC class I molecules. However, the
effect of TAPBPR depletion on HLA-A2 thermal stability was not as severe as that observed in the
absence of tapasin (compared red and blue bars in Figure 8B). The thermal stability of peptide
loaded HLA-A2 was further decreased when TAPBPR was depleted in tapasin negative cells (green
bar in Figure 8B). These results are consistent with the decreased steady state levels of HLA-A2
observed in TAPBPR depleted and tapasin deficient cells as shown in Figure 8A.
Next, to examine whether MHC class I complexes with lower stability are released onto the cell
surface in the absence of TAPBPR, we examined the decay rates of MHC class I molecules expressed
at the cell surface in TAPBPR-competent and TAPBPR-depleted cells. Both HLA-A2 and –B7 exhib-
ited faster decay rates from the cell surface in TAPBPR-depleted cells (Figure 8E‚F), suggesting that
in the absence of TAPBPR MHC class I molecules containing lower affinity peptides can escape to
the cell surface. For HLA-A2, tapasin deficiency had a more severe effect than TAPBPR depletion on
the rate of decay (compare the blue line with the red line in Figure 8E) while for HLA-B7, tapasin
deficiency and TAPBPR depletion had a similar effect on the decay rate (see the overlap of the blue
and red line in Figure 8F). For both HLA-A2 and –B7 the loss of both tapasin and TAPBPR had an
accumulative effect on MHC class I stability (see green line in Figure 8E,F). Together, these results
clearly demonstrate a role for TAPBPR in the selection of stable peptides for MHC class I molecules
in vivo and support the hypothesis that TAPBPR can enhance peptide optimisation in the absence of
tapasin.
Discussion
The PLC is considered to be the major site where MHC class I molecules are loaded with high affinity
peptides, with the tapasin-ERp57 conjugate described as the functional unit (Momburg and Tan,
2002; Williams et al., 2002; Howarth et al., 2004; Wearsch and Cresswell, 2007). Our experi-
ments indicate that TAPBPR is also involved in peptide selection for MHC class I molecules. Like
tapasin, TAPBPR can catalyse the dissociation of peptides from peptide-MHC I complexes, enhance
the loading of peptide-receptive MHC I molecules, and discriminate between peptides based on
affinity in vitro. Therefore, it is now apparent that there are two MHC class I specific peptide
exchange catalysts in the antigen presentation pathway intimately involved in selecting peptide for
presentation to the immune system.
We found that the luminal domains of TAPBPR were able to efficiently function in MHC class I
peptide selection in vitro. This suggests that the luminal region of TAPBPR alone has sufficient affin-
ity for MHC class I to promote peptide loading and to catalyse peptide exchange and does not
require other co-factors or to be artificially tethered to MHC class I to perform this function. This is
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in contrast to soluble tapasin, which others have found does not associate productively with MHC
class I in vitro alone, and instead requires either conjugation to ERp57 or to be artificially tethered to
MHC class I (Chen and Bouvier, 2007; Wearsch and Cresswell, 2007). We speculate the difference
in affinity of tapasin and TAPBPR for MHC class I may have evolved as a consequence of the distinct
cellular environment the two peptide exchange catalysts function: tapasin functioning in the context
of the PLC, where other proteins collectively form a mutually supportive interaction scaffold, and
TAPBPR functioning outside the confines of the PLC. Although both tapasin and TAPBPR clearly
function as peptide exchange catalysts in vitro, the activities of the two proteins are not identical.
Firstly, we observed differences in the ability of tapasin-jun and TAPBPR to promote dissociation of
peptides from HLA-A*02:01. Secondly, we found TAPBPR was unable to promote the binding of
ELRSRK*WAI or FLRGRK*YGL to peptide recep-
tive HLA-B*08:01fos molecules, whereas Chen &
Bouvier found that tapasin-jun enhanced the
binding of FITC labelled variants of both these
peptides (Chen and Bouvier, 2007). This indi-
cates there are some qualitative differences
between the activity of TAPBPR and tapasin.
Clearly, a new picture concerning how pepti-
des are selected for presentation by MHC class I
molecules is emerging. Our findings are consis-
tent with tapasin and TAPBPR working together
in a sequential manner (Figure 9). The initial pep-
tide loading of MHC I molecules is likely to occur
within the PLC and to be assisted by tapasin.
Within this relatively peptide-rich environment,
peptide loading and exchange mediated by tapa-
sin increases the affinity of peptide bound to
MHC class I. We propose that outside of the
PLC, the stability of peptide:MHC I complexes is
monitored by TAPBPR. Those molecules loaded
with high affinity peptides will either circumvent
TAPBPR-mediated peptide editing completely or
pass through this quality control checkpoint. For
MHC class I molecules loaded with peptides of
intermediate or low affinity, TAPBPR-mediated
peptide editing proceeds. The unique environ-
ments in which tapasin and TAPBPR have evolved
to operate in are likely to shape the peptide rep-
ertoire in different ways. The relatively peptide-
rich environment of the PLC may allow tapasin to
promote peptide binding and produce a rela-
tively broad peptide repertoire. However, pre-
sumably as an MHC I molecule moves away from
the PLC, the gradient of optimal peptides is likely
to decrease and therefore TAPBPR-mediated
peptide editing events within such an environ-
ment may favour peptide dissociation rather than
association. Thus we speculate that, in a peptide
rich environment, acceleration of both association
and dissociation (by tapasin) contributes to edit-
ing; while in a peptide dilute environment, accel-
eration of dissociation only (by TAPBPR) may
dominate editing, consistent with the increased
peptide repertoire observed in TAPBPR deficient
cells. Thus, TAPBPR may restrict peptide
Figure 9. Model of the relationship between tapasin
and TAPBPR in shaping the peptide repertoire
expressed on MHC class I. (A) Upstream of the PLC, in
an environment in which peptides suitable for MHC
class I binding are likely to be at a low concentration,
TAPBPR might help stabilise a peptide-receptive
conformation of MHC class I, but would not directly
assist in peptide loading, peptide exchange or directly
increase the abundance of peptide:MHC complexes
due to a shortage of peptide. (B) The optimal peptide
loading environment for MHC class I is presumably
within the PLC where the concentration of peptides
suitable for MHC class I is the highest and where MHC
I are held in a peptide-receptive conformation by
tapasin. (C) Once peptide:MHC I complexes are
released from the PLC, TAPBPR-mediated dissociation
would attempt to remove peptide from MHC class I. If
a high affinity peptide was bound to the MHC I
molecules, TAPBPR would not be able to remove it. If
TAPBPR can cause the dissociation of peptide, peptide
exchange could ensue if suitable replacement peptides
were available. However, the further away from the PLC
and/or the further down the MHC class I peptide
gradient TAPBPR works there may be a shortage of
suitable replacement peptides. In this situation TAPBPR
is unlikely to load the peptide-receptive MHC class I
and may assist in the recycling of MHC I molecules. By
functioning as a peptide exchange catalyst in a
relatively peptide deficient environment, TAPBPR could
increase the affinity of the peptide:MHC I complexes or
restrict the diversity of peptide:MHC I complexes which
are presented to the cell surface.
DOI: 10.7554/eLife.09617.015
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presentation by enhancing the selection of high affinity peptide on MHC class I.
Further in-depth analysis is required to dissect the intricate relationship between tapasin and
TAPBPR in determining the final peptide repertoire presented on the cell surface. In particular it will
be important to understand how different MHC class I allomorphs depend on these two specific
chaperones. Intriguingly, we have observed differences in the functional effects of TAPBPR on pep-
tide selection by HLA-A2 and –B7. For HLA-A2, TAPBPR catalyses both the peptide dissociation and
association in vitro, in a similar manner described for the function of tapasin, albeit with different
peptide preference. Therefore, there may be shared, but not identical, functionality between tapasin
and TAPBPR regarding peptide selection onto HLA-A2, i.e. in a peptide abundant environment both
chaperones could potentially load and edit peptides bound to HLA-A2. This may explain, at least in
part, why surface expression of HLA-A2 is relatively tapasin-independent (Lewis et al., 1998). Sur-
face expression of HLA-A2 is also TAPBPR-independent in the presence of tapasin, and it is not until
tapasin and TAPBPR are absent or depleted that a severe effect is observed on HLA-A2 surface
expression. In the absence of both tapasin and TAPBPR, surface expression of HLA-A2 resembles
that of the HLA-A2 T134K mutant (Lewis et al., 1996; Peace-Brewer et al., 1996). Therefore the
discovery of a peptide editing function for TAPBPR helps explain the previous discrepancies regard-
ing the phenotype of the T134K mutant (in which the HLA-A2 mutant is unable to interact with either
tapasin or TAPBPR and exhibits low cell surface expression) and tapasin-deficient cells (in which the
HLA-A2 binds TAPBPR and exhibits high cell surface expression).
Our results clearly demonstrate that TAPBPR also plays a significant role in peptide selection by
HLA-B molecules. This importance of TAPBPR in HLA-B biology was underappreciated previously
when investigating the interaction between TAPBPR and HLA-B in HeLa cells (Boyle et al., 2013).
Although all the HLA-B molecules investigated here (HLA-B7, -B8, -B15 and -B40) exhibit weak or
transient association with TAPBPR as compared to HLA-A2 in wild-type cells, the interaction
between HLA-B7 and TAPBPR was significantly increased in the absence of tapasin as shown in Fig-
ure 8. TAPBPR clearly influenced peptide selection on all of these HLA-B molecules: fluorescent
polarisation experiments demonstrate that TAPBPR functions as a peptide loading and exchange
catalyst for EIYK*RWIIL on HLA-B8; TAPBPR deficiency in IFN-g induced HeLa and KBM-7 cells alters
the peptide repertoire expressed by HLA-B15 and HLA-B40 respectively; and depletion of TAPBPR
in 721.221 results in a significant decrease in the surface expression of HLA-B7, even in the presence
of tapasin. Taken together, these results suggest that TAPBPR is responsible for restricting peptides
on HLA-B allomorphs. Clearly, peptide selection by MHC class I molecules is far more complex than
previously anticipated. Given that a single T-cell receptor (TCR) can in principle see many different
peptide-MHC class I complexes (Sewell, 2012; Wooldridge et al., 2012), the two MHC specific
chaperones of the MHC class I antigen presentation pathway, may be the crucial influence in select-
ing immune responses.
Materials and methods
Expression and purification of TAPBPR proteins
The luminal domains of TAPBPR and TAPBPRTN5 (I261K) (Hermann et al., 2013) were cloned into
pHLsec containing a C-terminal His-tag and an N-terminal signal sequence (Aricescu et al., 2006).
To produce secreted TAPBPR and TAPBPRTN5, 250 mg of the TAPBPR pHLsec plasmids were mixed
with 1.5 ml of 1 mg/ml PEI 25K (Sigma, St Louis, MO) in 25 ml phosphate-buffered saline (PBS), fol-
lowed by incubation at room temperature for 20 min. The solution was added dropwise to HEK293F
cell in FreeStyleTM 293 Expression Medium (Gibco, Thermo Fisher Scientific, UK) seeded at a density
of 1  106 cells/ml in a volume of 250 ml in a 1 L Erlenmeyer conical tissue flask and incubated for
three days at 37˚C under constant shaking at 125 rpm. The cell culture supernatant was harvested,
filtered and purified using Ni-NTA affinity chromatography (Invitrogen, Thermo Fisher Scientific).
Beads were isolated, washed in 20 mM Tris pH 7.4, 200 mM NaCl, 20 mM Imidazole and TAPBPR
was eluted with 20 mM Tris pH 7.4, 200 mM NaCl, 300 mM Imidazole. Protein-containing fractions
were analysed by SDS-PAGE followed by Coomassie staining, pooled and concentrated. The con-
centrate was exchanged into 50 mM Tris, 150 mM NaCl pH 8.0 buffer and separated on a Superdex
S200 10/300 column (GE Heathcare, UK) by size exclusion chromatography. Protein-containing
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fractions were analysed by SDS-PAGE followed by Coomassie staining, pooled and further concen-
trated. The concentrate was snap frozen in liquid nitrogen and stored at -80˚C.
Differential scanning fluorimetry (DSF)
DSF experiments were performed in 48-well plates using 50 mL reactions consisting of 2 mg of puri-
fied TAPBPR protein and 5x SyPRO orange dye (Invitrogen molecular probes, Thermo Fisher Scien-
tific) in PBS pH 7.4. The melt curve was performed using Bio-Rad MiniOpticon reverse transcription-
polymerase chain reaction (RT-PCR) thermal cycler between 20˚C and 95˚C in 1˚C steps with 20 s
equilibration time per step. The protein melting temperature (Tm) was taken as the inflexion point of
the sigmoidal melting curve, obtained by curve fitting using DSF scripts (Niesen et al., 2007) and
GraphPad Prism software.
Production of plasmids encoding MHC I and MHC I-fos proteins
pHN1+ plasmids encoding the mature human beta 2-microglobulin protein (b2m hereafter) or the
ER luminal domains of HLA A*02:01 protein with C-terminal BirA motif were obtained from Prof P
Moss (University of Birmingham, UK). pGM-T7 plasmids encoding the ER luminal domains of wild-
type HLA B*08:01 or the T134K point mutant, each with C-terminal fos leucine zipper sequences,
were provided by Prof M Bouvier (Chen and Bouvier, 2007). The sequence encoding HLA-
B*08:01fos or the T134K point mutant were excised by restriction enzyme digestion and sub-cloned
into pET22b plasmid (Novagen, Merck Millipore, Germany). DNA encoding the ER luminal domains
of HLA A*02:01 with C-terminal Fos leucine zipper sequence was created by PCR: nucleotides
encoding the ER luminal domains of A*02:01 were amplified using primers 5’-GATATACCATGGGC-
TCTCACTCC-3’ and 5’-CGGAACCTCCCTCCCATC-3’ and pHN1 A*02:01 DNA; while nucleotides
encoding the Fos leucine zipper were amplified from pET22b HLA B*08:01fos using primers 5’- GG-
AGGTTCCGGCGGTC-3’ and 5’-CGCAAGCTTTTAATGGGCGG-3’. The purified products from both
PCR reactions were used in a third PCR reaction to create A*02:01fos using primers 5’-GATATACC-
ATGGGCTCTCACTCC-3’ and 5’-CGCAAGCTTTTAATGGGCGG-3’.
Following agarose gel electrophoresis and digestion of the purified product with restriction
enzymes the sequence encoding HLA-A*02:01fos was cloned into pET22b.
Production of tapasin-jun proteins
DNA encoding His tagged human tapasin-jun (Chen and Bouvier, 2007) was amplified by PCR using
5’-GTCAGATCTGGACCCGCGGTGATCG-3’ and 5’-CTCGGTACCCTAATGGTGATGGTGATG-3’ pri-
mers, and ligated to pMT/BiP plasmid (Invitrogen, Thermo Fisher Scientific) following agarose gel
electrophoresis and digestion of the purified product with BglII and KpnI restriction enzymes. The
His6 tag present in the Jun leucine zipper portion was then replaced by PCR mutagenesis with an
HA epitope using 5’-GTCAGATCTGGACCCGCGGTGATCG-3’ and 5’-GTAGGTACCCTAAGCGTAG-
TCTGGGACGTCGTATGGGTAGTTCATGACTTTCTG-3’ primers. The resulting DNA (encoding the
luminal domains of human tapasin, GGSGG linker, thrombin cleavage site, Jun leucine peptide, HA
tag, and stop codon) was transferred by restriction enzyme digestion to pMT/BiP plasmid modified
to encode puromycin resistance. Stable polyclonal transfectants of S2 cells were obtained by trans-
fecting 1 mg of tapasin-jun DNA using Fugene 6 (Roche Applied Science, UK), and puromycin selec-
tion. Transfectants were adapted to EX-CELL 420 Serum-Free Medium (Sigma), and tapasin-jun
expression was induced with 500 mM CuSO4. Supernatants were harvested 6 days later. Tapasin-jun
was captured using anti-HA-agarose (Sigma), washed with 20 mM Tris pH7.4, 150 mM NaCl and
eluted using 1 mg/ml HA peptide in 20 mM Tris pH 7.4, 150 mM NaCl. SDS PAGE electrophoresis
and Coomassie staining was used to select fractions containing high concentrations of tapasin-jun,
which were dialysed against 20 mM Tris-HCl pH 7.5, 150 mM NaCl at 4˚C. The protein was snap fro-
zen in liquid nitrogen and stored at -80˚C.
Peptides
The following HLA-A*02:01 binding peptides were used: the UV-labile peptide KILGFVFjV (j rep-
resents 3-amino-3-(2-nitro) phenyl-propionic acid), the fluorescent peptides FLPSDC*FPSV,
KLWEAESK*L, FLLAEDTK*V, KLVK*EVIAV, YLVAEK*VTV, GLDDIKDLK*V, YLENGK*ETL (C* and K*
denotes TAMRA labelled cysteine or lysine), non-labelled peptides FLPSDCFPSV, NLVPMVATV
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and three variants of this peptide NAVPMVATV (D2), NLVPMVATM (D9), NAVPMVATM (D2/9).
The following HLA-B*08:01 binding peptides were used: the UV-labile peptide FLRGRAjGL, the
fluorescent peptides ELRSRK*WAI, EIYK*RWIIL or FLRGRK*YGL (K* denotes TAMRA labelled
lysine), and the non-labelled peptides ELRSRKWAI, EIYKRWIIL or FLRGRKYGL. Tamra labelled
and unlabelled peptides used in fluorescence polarisation were synthesised by GL Biochem Ltd
(Minhang, Shanghai). All other peptides were synthesised by Peptide Protein Research Ltd (Funt-
ley, Fareham, UK).
Production of peptide-loaded MHC I or MHC I-fos complexes
Peptide-loaded MHC I or MHC I-fos complexes were obtained as in (Garboczi et al., 1992) by
refolding solubilized inclusion bodies of MHC I or MHC I-fos heavy chains with solubilized inclusion
bodies of human b2m and UV-labile MHC class I specific peptides.
Fluorescence polarization experiments
Fluorescence polarization measurements were taken using an Analyst AD (Molecular Devices) with
530 nm excitation and 580 nm emission filters and 561 nm dichroic mirror. All experiments were con-
ducted at room temperature in duplicate and used PBS supplemented with 0.5 mg/ml bovine
gamma-globulin (Sigma) and 0.5 mM dithiothreitol, in a volume of 60 ml. Binding of TAMRA-labelled
peptide is reported in millipolarisation units (mP) and is obtained from the equation, mP = 1000  (S
- G  P)/(S + G  P), where S and P are background-subtracted fluorescence count rates (S = polar-
ised emission filter is parallel to the excitation filter; P = polarised emission filter is perpendicular to
the excitation filter), and G (grating) is an instrument- and assay-dependent factor.
Dissociation rate measurements
Peptide-receptive HLA-A*02:01 and HLA-B*08:01 were obtained by exposing the monomeric MHC
class I complexes loaded with UV labile peptides to ~360 nm light for 20 min at 4˚C (’UV exposed’
hereafter). MHC class I molecules were allowed to bind to fluorescent peptides overnight at 4˚C.
Dissociation of the fluorescent peptide was subsequently followed at room temperature after the
addition of excess non-labelled competitor peptide in the absence or presence of TAPBPR,
TAPBPRTN5 or tapasin-jun.
Association rate measurements
The binding of fluorescent peptides to UV-exposed MHC class I was monitored in the absence and
the presence of TAPBPR or TAPBPRTN5.
Peptide competition experiments
The binding of fluorescent peptide to MHC class I was monitored in the presence of a titration of
non-labelled competitor peptides without and with TAPBPR or TAPBPRTN5. Fluorescence polariza-
tions measurements were taken after being left at room temperature overnight.
Antibodies
The following TAPBPR specific antibodies were used: PeTe4 (a mouse mAb raised against the
luminal domains of human TAPBPR which recognise a native conformation of the protein)
(Boyle et al., 2013), R014 (a rabbit polyclonal raised against the luminal domains of human
TAPBPR), R021 (a rabbit polyclonal raised against the cytoplasmic tail of human TAPBPR), a
mouse anti-TAPBPR mAb raised against the membrane distal domain of TAPBPR (ab57411,
Abcam, UK). The following MHC class I specific antibodies were used: HC10 (a mouse mAb that
recognises a PxxWDR motif at aa 57–62 in the a1 domain of the MHC class I heavy chain, found
commonly in HLA-B and –C, and also in a few HLA-A allomorphs) (Stam et al., 1986;
Perosa et al., 2003), HCA2 (a mouse mAb that recognises HLA allomorphs containing a
xLxTLRGx motif at aa 77–84 on the a1 domain) (Stam et al., 1990 Sernee et al., 1998), 3B10.7
(a rat monoclonal antibody with broad specificity for HLA I independent of conformation)
(Lutz and Cresswell, 1987), BB7.2 (a mouse mAb specific for b2m bound and peptide loaded
HLA-A2), Bw6 (a mouse mAb specific for MHC class I allomorphs containing the Bw6 epitope
SLRNLRG at aa 77–83) (One Lambda, Thermo Fisher Scientific, Canoga Park, CA), BB7.1 (a
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mouse mAb specific for HLA-B7) (AbDSerotec), W6/32 (a pan MHC I mAb which recognises a
conformation epitope on the MHC I a2 domain, dependent on b2m and peptide)
(Barnstable et al., 1978), 4E (a mouse monoclonal reactive against HLA-B as well as a limited
number of HLA-A molecules (A29, Aw30, Aw31, Aw32) (Yang et al., 1984), B1.23.2 (a mouse
mAb that recognises both b2m association and -free HLA-B,-C as well as some HLA-A heavy
chains) (Rebaı¨ and Malissen, 1983; Apps et al., 2009). Other antibodies used were Pasta1 (a
mAb which recognises native tapasin) (Dick et al., 2002) and Rpg48N (tapasin specific rabbit
polyclonal) (both kind gifts from Peter Cresswell, Yale University School of Medicine, New Haven,
CT), and rabbit anti-calnexin (Enzo life Sciences, UK). Primary antibodies were detected with
horseradish peroxidase (HRP) conjugated secondary antibodies (Dako, UK) and goat-anti-mouse
Alexa 647 (molecular probes). In addition isotype control antibodies were also used (Dako).
Cell lines
HEK293T were maintained in Dulbecco’s modified eagle’s medium (DMEM;Gibco), HeLa-M, HeLa-S,
HeLa-S depleted of TAPBPR using shRNA (Boyle et al., 2013), 721.221 and 721.220 cells were main-
tained in Roswell Park Memorial Institute (RMPI) 1640 media (Gibco), and KBM-7 cells were main-
tained in Iscove’s Modified Dulbecco’s Medium (Gibco) all supplemented with 10% fetal calf serum,
100 U/ml penicillin and 100 mg/ml streptomycin (Gibco) at 37˚C and 5% CO2. To induce
the expression of endogenous TAPBPR, cells were treated with 50 U/ml of IFN-g (Peprotech, UK) at
37˚C for 48–72 hr.
Plasmids and transductions
HLA-A*02:01, -A*68:01, -B*08:01, -B*15:10 and –B*40:02 were cloned into the lentiviral vector
pHRSINcPPT-SGW. HLA-B*07:02 was cloned into the lentiviral vector pHRSIN-C56W-UbEM produc-
ing HLA-B7 under the spleen focus-forming virus promotor and the green fluorescent protein (GFP)-
derivative protein emerald under an ubiquitin promotor. For TAPBPR depletion, the lentiviral shRNA
plasmid V2LHS_135531 on the pGIPZ backbone was used (Open Biosystems, GE healthcare). Lentivi-
ral plasmids were transfected into HEK-293T cells along with the packaging plasmid pCMVR8.91
and envelope plasmid pMD-G using TransIT-293 (Mirus, Madison, WI). Forty eight and seventy two
hours post-transfection, the filtered supernatants were used to transduce HeLa, 721.221 or 721.220
cells. For HLA molecules transduced into 721.221, the transduction efficiency was determined by
the surface expression of MHC class I using W6/32 antibody with flow cytometry. To make the
721.221 and 721.220 expressing both HLA-A2 and –B7, HLA-A2 was first stably transduced into the
cell lines with transduction efficiency determined by surface expression of HLA-A2 using BB7.2 anti-
body with flow cytometry. These HLA-A2 positive cells were subsequently transduced with HLA-B7
pHRSIN-C56W-UbEM with transduction efficiency determined by GFP expression in the cells. To
select cells depleted of TAPBPR puromycin selection was used post transduction with
V2LHS_135531.
Generation of HeLa TAPBPR knock-out cell lines using CRISPR
HeLa TAPBPR KO lines were generated using CRISPR as previously described (Ran, et al.,
2013). To target TAPBPR expression, sgRNAs were chosen using the CRISPR design tool
(http://crispr.mit.edu), which bind in exon 2 of TAPBPR (Crispr7: GCGAAGGACGGTGCGCACCG)
and cloned into pSpCas9(BB)-2A-Puro. To generate HeLa TAPBPR KO cell lines, cells were
seeded at a confluence of 80% in 6 well format and transfected with TAPBPR-CRISPR plasmids
in the absence of serum using Lipofectamine2000 (Invitrogen, Thermo Fisher Scientific). Twenty
four hours after transfection, the medium was replaced with complete DMEM containing 4 mg/
ml puromycin (Invivogen, San Diego, CA). After 48 hr, the medium was replaced with complete
DMEM without puromycin. Subsequently, the clones were selected and the absence of TAPBPR
protein was verified by immunoprecipitation/western blot analysis.
Immunoprecipitation and western blot analysis
Harvested cells were washed in PBS, pelleted, then lysed in either 1% digitonin (Merck Millipore)
Tris-buffered saline (TBS) (20 mM Tris-HCl pH7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM ethylenediami-
netetraacetic acid) supplemented with 10 mM N-ethylmaleimide (NEM) (Sigma), 1mM
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phenylmethylsulfonyl fluoride (PMSF; Sigma) and protease inhibitor cocktail (Roche) for 30 min at
4˚C. Nuclei and cell debris were pelleted by centrifugation at 13,000  g for 10 min and superna-
tants were precleared on IgG-sepharose (GE Healthcare, United Kingdom) and Protein A Sepharose
(Generon, UK) for 1 hr at 4˚C with rotation. Immunoprecipitation was performed with the indicated
antibody and Protein A Sepharose for 1 hr at 4˚C with rotation. Following immunoprecipitation,
the beads were washed thoroughly in 0.1% detergent-TBS to remove the unbound protein. All sam-
ples were heated at 80˚C for 10 min in reducing sample buffer (125 mM Tris-HCL pH 6.8, 4% SDS,
20% glycerol, 0.04% bromophenol blue with 100 mM b-mercaptoethanol). Proteins were separated
by SDS-PAGE and transferred onto an Immobilon transfer membrane (Millipore, Billerica, MA). Mem-
branes were blocked using 5% (w/v) dried milk, 0.1% (v/v) Tween 20 in PBS for 30 min, followed by
incubation with the indicated primary antibody for 1 hr. After washing, membranes were incubated
with species-specific HRP conjugated secondary antibodies, before detection by enhanced chemilu-
minescence reagent (GE Healthcare).
MHC class I thermal stability assays
Cells were starved in methionine and cysteine free RPMI for 30 min at 37˚C, then labelled using
EasyTag Express [35S]-protein labeling mix (Perkin Elmer) for 60 min at 37˚C. Cells were lysed in
1% Triton X-100 (Sigma) TBS containing 10 mM NEM, 1 mM PMSF and protease inhibitors for
30 min at 4˚C. Equal aliquots of clarified cell lysates were either kept at 4˚C or heated at 22, 37
or 50˚C for 12 min, before returning to 4˚C. Immunoprecipitation and SDS-PAGE were performed
as above. Gels were subsequently fixed in 12% acetic acid, 40% methanol and dried. Images
were obtained using a phosphor screen (Perkin-Elmer) or on film. PhosphorImager analysis was
performed using Typhoon Trio variable mode imager (GE Healthcare) together with Image-
QuantTL software. Densitometry of the MHC class I HC band was performed. The amount of
recoverable HLA-A2 remaining at each temperature was determined as a percentage of the sig-
nal intensity at 4˚C. Graphs were generated using GraphPad Prism software. High-resolution
images were obtained using film.
Flow cytometry
Cells were washed in PBS, then incubated for 20 min at 4˚C with W6/32, BB7.2, BB7.1, 4E or a HLA-
Bw6 specific antibody. Isotype control antibodies were used as negative controls. Cells were washed
in ice-cold PBS, then the bound primary antibody was subsequently detected with species-specific
Alexa Fluor 647 secondary antibodies (Molecular Probes). Cells were analysed on a BD FACS Calibur
4-(BD Biosciences, East Rutherford, NJ) colour analyser and data were analysed using FlowJo soft-
ware. For MHC class I cell surface decay experiments, 5 mg/ml brefeldin A was incubated with cells
for 0, 0.5, 3, 6, and 16 hr followed by staining with BB7.2 or BB7.1.
MHC class I peptide analysis
HLA ligands from 5  108 cells per cell line were isolated by immunoaffinity chromatography. Cells
were lysed in buffer containing PBS, 0.6% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), and Complete protease inhibitor, shaken for 1 hr at 4˚C and subse-
quently sonicated for 1 min. Following centrifugation for 1.5 hr to remove debris, the supernatant
was applied on affinity columns overnight at 4˚C. Columns were previously prepared by coupling
antibodies to CNBr-activated Sepharose (GE Healthcare, Buckinghamshire, England) (1 mg anti-
body/40 mg Sepharose). The antibody W6/32 was used to isolate all HLA class I alleles in HeLa cells.
For KBM-7 cells, BB7.2 was used to isolate HLA-A2 and B1.23.2 was used to isolate HLA-B and -C
molecules.
On the second day the columns were eluted in eight steps using 0.2% trifluoroacetic acid.
The eluate was passed through a 10 kDa filter (Merck Millipore, Darmstadt, Germany) to yield
the HLA-ligands in solution. The filtrate was desalted with C18 ZipTips (Merck Millipore, Darm-
stadt, Germany) and subsequently concentrated using a vacuum centrifuge (Bachofer, Mu¨nchen,
Germany). Sample volume was adjusted for measurement by adding 1% ACN/0.05% TFA (v/v).
With an injection volume of 5 ml HLA ligands were loaded (100 mm  2 cm, C18, 5 mm, 100 A˚)
and separated (75 mm  50 cm, C18, 3 mm, 100 A˚) on Acclaim Pepmap100 columns (Dionex,
Sunnyvale, CA) using an Ultimate 3000 RLSCnano uHPLC system (Dionex). A gradient ranging
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from 2.4 to 32% of ACN/H2O with 0.1% formic acid was used to elute the peptides from the
columns over 140 min at a flow rate of 300 nl/min. Online electrospray ionisation (ESI) was fol-
lowed by tandem mass spectrometry (MS) analysis in a LTQ Orbitrap XL instrument (Thermo-
Fisher Scientific, Bremen, Germany). Survey scans were acquired in the Orbitrap mass analyzer
with a resolution of 60,000 and a mass range of 400–650 m/z. Peptides with a charge state other
than 2+ or 3+ were rejected from fragmentation. Fragment mass spectra of the five most intense
ions of each scan cycle were recorded in the linear ion trap (top5 CID). Normalised collision
energy of 35%, activation time of 30 ms and isolation width of 2 m/z was utilised for fragment
mass analysis. Dynamic exclusion was set to 1 s. The rawwere processed against the human pro-
teome as comprised in the Swiss-Prot database (www.uniprot.org, status: Dec12th, 2012; 20.225
reviewed sequences contained) using MASCOT server version 2.3.04 (Matrix Science, Boston,
MA) and Proteome Discoverer 1.4 (Thermo Fisher Scientific). Oxidation of methionine was
allowed as dynamic peptide modification. A mass tolerance of 5 ppm or 0.5 Da was allowed for
parent- and fragment masses respectively. Filtering parameters were set to a Mascot Score<20,
search engine rank = 1, peptide length of 8-12 AA, achieving a false discovery rate (FDR) of 5%
as determined by an inverse decoy database search. The netMHC programme (http://www.cbs.
dtu.dk/services/NetMHC/) was used to predict the binding of peptides to specific HLA allo-
morphs (Lundegaard et al., 2008a, 2008b). To determine classic peptide anchor conservation,
TAPBPR permitted peptides (shared peptides) and TAPBPR restricted peptides (peptides unique
to HeLa-TAPBPR KO cells or peptides unique to HeLa cells) were compared and the frequency
of classic anchors at P2 or PW calculated for both HLA-A*68:02 or HLA-B*15:03.
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